Also trades as: ESLA (NASDAQ) · $vol 0M
ESLAW NASDAQ
Estrella Immunopharma, Inc.
1W: +0.1%
1M: +49.7%
3M: -4.3%
YTD: +49.9%
1Y: +272.6%
$0.13
+0.02 (+22.64%)
Weekly Expected Move ±54.4%
$-0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$4.8M
52W Range0.11-0.1349
Volume0
Avg Volume12,323
Beta-0.09
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOCheng Liu
Employees3
SectorHealthcare
IndustryBiotechnology
IPO Date2023-10-02
Websiteestrellabio.com
5858 Horton Street
EmeryVille, CA 94608
US
EmeryVille, CA 94608
US
510 318 9098
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Xu Jiandong | P-Purchase | 1,000 | $1.33 | 2025-10-07 |
| Xu Jiandong | P-Purchase | 1,000 | $1.16 | 2025-09-22 |
| Jia Dengyao | 0 | — | 2025-09-22 | |
| Xu Jiandong | P-Purchase | 100 | $1.04 | 2025-09-11 |
| Liu Cheng | A-Award | 509,204 | $0.81 | 2024-10-30 |